Hims & Hers Health (HIMS) saw its stock drop 4.03% to $29.76 on Tuesday, following Amazon’s launch of a competing GLP-1 weight-loss program. Despite this setback, HIMS has experienced a remarkable 39.33% surge over the past week, driven by positive news regarding FDA policy changes and a legal resolution with Novo Nordisk. Trading volume reached 56.7 million shares, significantly above its three-month average, indicating heightened investor interest.
The broader market reflected cautious sentiment, with the S&P 500 and Nasdaq Composite both declining. Telehealth peers like Teladoc Health and American Well also faced losses, highlighting sector-wide pressures. Amazon’s entry into the weight-loss arena poses a significant threat to Hims & Hers, particularly given its established logistics capabilities that could challenge HIMS’ market position.
Investors should closely monitor Hims & Hers’ upcoming Q1 results on May 11, as the impact of Amazon’s competitive move on revenue and subscriber growth will be critical for assessing the company’s future trajectory.
Source: fool.com